Chicago Biosolutions, Inc.
Chicago, IL · Biotech · Private
Small molecule inhibitors that block influenza A virus entry
- Grants
- $13M
- 18 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152017201920212023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · 4-Aminopiperidines as novel anti-influenza agents | $242,913 | |
| Federal grant | Department of Health and Human Services · Phase I · Aminopiperidines as novel anti influenza agents | $396,096 | |
| Federal grant | Department of Health and Human Services · Phase I · 4-(Aminomethyl) benzamides as novel anti-Ebola agents | $363,601 | |
| Federal grant | Department of Health and Human Services · Phase I · Aminomethyl benzamides as novel anti Ebola agents | $727,199 | |
| Federal grant | Department of Health and Human Services · Phase I · Furopyrroles as Novel anti-Ebola Agents | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · 4-Aminopiperidines as novel anti-influenza agents | $153,183 | |
| Federal grant | Department of Health and Human Services · Phase I · 4-(Aminomethyl) benzamides as novel anti-Ebola agents | $363,598 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of group 2 influenza A virus entry inhibitors | $599,998 | |
| Federal grant | Department of Health and Human Services · Phase II · 4-(Aminomethyl) benzamides as novel anti-Ebola agents | $2,916,523 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of group 2 influenza A virus entry inhibitors | $299,999 | |
| Federal grant | Department of Health and Human Services · Phase II · 4-(Aminomethyl) benzamides as novel anti-Ebola agents | $961,660 | |
| Federal grant | Department of Health and Human Services · Phase I · Furopyrimidines as novel inhibitors of henipaviruses | $599,262 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · 4-(Aminomethyl) benzamides as novel anti-Ebola agents | $982,388 | |
| Federal grant | Department of Health and Human Services · Phase I · Furopyrimidines as novel inhibitors of henipaviruses | $299,667 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | $1,998,738 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | $999,369 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | $999,234 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1726 | FAUNA BIO INCORPORATED | — | — |
| 1727 | Zyversa Therapeutics, Inc. | — | $3.6M |
| 1728 | PYROJAS INC | — | — |
| 1729 | Chicago Biosolutions, Inc. | — | — |
| 1730 | DEMERX, INC. | — | $290K |
| 1731 | Design Therapeutics, Inc. | — | $171M |
| 1732 | Halia Therapeutics, Inc. | — | $27M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Inhibitors Of Influenza Viral Entryapplication
- Inhibitors Of Influenza Viral Entryapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.